Previous 10 | Next 10 |
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical Oncology (ASCO) Annu...
Vaccinex ( VCNX -1.5% ) announces full enrollment (n=62) in a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating lead candidate pepinemab (VX15/2503), combined with Pfizer's ( PFE +0.6% ) Bavencio (avelumab), in patients with advanced non-small cell lung cancer (NSCLC). Mor...
63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated in second half of 2019 ROCHESTER, N.Y., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex...
Ultra-thinly traded nano cap Vaccinex ( VCNX -9.2% ) is down on average volume, albeit on turnover of only 6K shares, in reaction to its private placement of ~3.4M common shares at $4.08 per share to a group of investors. More news on: Vaccinex, Inc., Healthcare stocks news, Stocks on ...
ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that the company entered into a stock purchase agreement pr...
The following slide deck was published by Vaccinex, Inc. in conjunction with this Read more ...
ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pep...
Vaccinex (NASDAQ: VCNX ): Q1 Revenue of $0.09M (-55.0% Y/Y) Cash and cash equivalents and marketable securities of $11.3M. Press Release More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, ,
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that two posters on its lead monoclonal antibody candidate, ...
Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019 Enrollment in Phase 2 SIGNAL Huntington’s disease trial complete; data expected in 2H 2020 ROCHESTER, N.Y., May 15, 2019 (GLO...
News, Short Squeeze, Breakout and More Instantly...
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pi...
2024-04-17 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...